Título 31. HEALTH · Capítulo 52. TERMINALLY ILL PATIENT’S RIGHT TO TRY INVESTIGATIONAL DRUGS, BIOLOGICAL PRODUCTS, AND DEVICES · Artículo 1. RIGHT TO TRY
31-52-4. Eligibility criteria.
Actualizado hasta: Including Acts of the 2025 Session of the General Assembly of Georgia.
El texto siguiente es la ley tal como la imprime el estado, en inglés.
In order for a person to be considered an eligible patient to access an investigational drug, biological product, or device pursuant to this article, a physician must document in writing that the person:
- (1)
Has a terminal illness;#
- (2)
Has, in consultation with the physician, considered all other treatment options currently approved by the federal Food and Drug Administration;#
- (3)
Has been given a recommendation by the physician for an investigational drug, biological product, or device; and#
- (4)
Has given written informed consent for the use of the investigational drug, biological product, or device.#
History
Code 1981, § 31-52-4, enacted by Ga. L. 2016, p. 345, § 1/HB 34; Ga. L. 2025, p. 455, § 3/SB 72, effective July 1, 2025.
Amendments
The 2025 amendment, effective July 1, 2025, substituted “article” for “chapter” in the first sentence of this Code section.
Editor's notes
Ga. L. 2025, p. 455, § 1/SB 72, not codified by the General Assembly, provides: “This Act shall be known and may be cited as the ‘Hope for Georgia Patients Act.’”
Leer la página oficial (el PDF del estado, abierto en la página de la que se leyó este texto).
Actualizado hasta: Including Acts of the 2025 Session of the General Assembly of Georgia.
Texto leído de t31-(v23)-2025-pdf.pdf, Volumen V23, edición 2025, páginas 1088 a 1089; acción de fusión: bound only; SHA-256 del archivo ba5a57f85d04.